Premium
Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I‐BFM analysis of 333 children
Author(s) -
Uden Theodor,
Bertaina Alice,
Abrahamsson Jonas,
Ansari Marc,
Balduzzi Adriana,
Bourquin JeanPierre,
Gerhardt Corinne,
Bierings Marc,
Hasle Henrik,
Lankester Arjan,
Mischke Kirsten,
Moore Andrew S.,
NivisonSmith Ian,
Pieczonka Anna,
Peters Christina,
Sedlacek Petr,
Reinhardt Dirk,
Stein Jerry,
Versluys Birgitta,
Wachowiak Jacek,
Willems Leen,
Zimmermann Martin,
Locatelli Franco,
Sauer Martin G.
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16441
Subject(s) - medicine , haematopoiesis , stem cell , transplantation , myeloid leukaemia , myeloid , hematopoietic stem cell transplantation , bone marrow , hematology , oncology , gastroenterology , immunology , biology , genetics
Summary Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four‐year probability of overall survival (4y‐pOS) was 14%. 4y‐pOS for 122 children receiving a second haematopoietic stem cell transplantation was 31% and 3% for those that did not ( P = <0·0001). Achievement of a subsequent remission impacted survival ( P = <0·0001). For patients receiving a second transplant survival with or without achieving a subsequent remission was comparable. Graft source (bone marrow vs. peripheral blood stem cells, P = 0·046) and donor choice (matched family vs. matched unrelated donor, P = 0·029) positively impacted survival after relapse. Disease recurrence and non‐relapse mortality at four years reached 45% and 22%.